| 产品描述: | ZD06519 (7-Hydroxyethyl carbamate-(10Me-11F-Camptothecin)) is a camptothecin analogue and a topoisomerase I inhibitor. ZD06519 is an ADC cytotoxin with a strong bystander effect, inhibiting a variety of malignancies such as HER2-positive and FRα-overexpressing tumors. ZD06519 inhibits DNA cleavage, relaxation, and reconnection processes, inducing tumor cell death. ZD06519 can be used for ADC synthesis and cancer research. |
| 体外研究: |
ZD06519 抑制肿瘤细胞活力,IC50 为 1 nM1。 |
| 体内研究: |
ZD06519-ADC (3–8 mg/kg;静脉注射;单剂量) 在免疫缺陷小鼠的 JIMT-1 乳腺癌、OV-90 卵巢癌、HT-29 结直肠癌等 CDX/PDX 模型中,显著抑制肿瘤生长,部分模型肿瘤完全消退且无明显体重下降或器官毒性。 |
| 参考文献: |
1. Petersen ME, et al. Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates. Mol Cancer Ther. 2024 May 2;23(5):606-618.
|
| 保存条件: |
2-8°C, 避光 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.01 ml |
10.051 ml |
20.102 ml |
| 5 mM |
0.402 ml |
2.01 ml |
4.02 ml |
| 10 mM |
0.201 ml |
1.005 ml |
2.01 ml |
| 50 mM |
0.04 ml |
0.201 ml |
0.402 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |